We are analyzing https://link.springer.com/article/10.1007/s00592-016-0892-7.

Title:
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials | Acta Diabetologica
Description:
EMPAREG OUTCOME study showed a reduction in cardiovascular events in patients treated with the sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin, as compared to placebo. Other drugs of the same class are currently been investigated for cardiovascular outcomes. In the meanwhile, a re-analysis of data collected in available studies can add relevant insight. A MEDLINE search for SGLT-2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, ertugliflozin, luseogliflozin) was performed, collecting all randomized trials up to November 16, 2015. All trials with a duration of treatment ≥12 weeks, enrolling patients with type 2 diabetes, comparing a SGLT2i with placebo or other comparators were included. The principal outcome was the effect of SGLT2i on all-cause and cardiovascular mortality. Secondary endpoints were myocardial infarction and stroke. Mantel–Haenszel odds ratio with 95 % confidence interval (MH-OR) was calculated. A total of 71 trials were included (31,199 and 16,088 patients in SGLT2i and comparator groups). Treatment with SGLT2i was associated with a significant reduction in all-cause mortality (MH-OR 0.70 [0.59–0.83], p < 0.001), cardiovascular mortality (MH-OR 0.43 [0.36–0.53], p < 0.001), and myocardial infarction (MH-OR 0.77 [0.63–0.94], p < 0.01), but not stroke (MH-OR 1.09 [0.86–1.38], p = 0.50), with no apparent difference across molecules (after excluding cardiovascular outcome trials). Available data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. The present meta-analysis showed a significantly reduction in myocardial infarction, with no increased risk of stroke.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Insurance

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

diabetes, article, pubmed, google, scholar, type, cas, patients, randomized, dapagliflozin, trial, metformin, study, cardiovascular, efficacy, safety, doubleblind, obes, metab, placebocontrolled, controlled, empagliflozin, mellitus, week, care, canagliflozin, central, inhibitors, accessed, jan, addon, monotherapy, inadequately, med, events, cotransporter, randomised, lancet, insulin, control, sglt, metaanalysis, mannucci, inhibitor, outcomes, treatment, effect, therapy, list, data,

Topics {✒️}

eu/docs/en_gb/document_library/epar_-_public_assessment_report/human/002649/wc500156457 eu/docs/en_gb/document_library/epar_-_product_information/human/002677/wc500168592 eu/docs/en_gb/document_library/epar_-_product_information/human/002322/wc500136026 gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm339293 month download article/chapter ilaria dicembrini & edoardo mannucci gov/ct2/show/nct01137474 placebo-controlled dose-finding study present meta-analysis showed gov/ct2/show/nct01649297 term=nct01340664&rank=1 kaku mantel–haenszel odds ratio understanding empa-reg outcome gov/ct2/show/nct01032629 gov/ct2/show/nct01730534 gov/ct2/show/nct01986881 gov/drugsatfda_docs/nda/2013/204042orig1s000medr gov/drugsatfda_docs/nda/2014/204629orig1s000medr gov/drugsatfda_docs/nda/2014/202293orig1s000medr platelet iib/iiia antagonist gov/ct2/show/nct01340664 sodium-glucose cotransporter-2 inhibitors sodium-glucose cotransport inhibition azienda ospedaliero-universitaria careggi edoardo mannucci designed term=canvas&rank=1 term=ertugliflozin+cardiovascular&rank=1 placebo-controlled clinical trial term=declare+dapagliflozin&rank=1 empareg outcome study blood pressure-lowering effect sodium-glucose cotransporter 2 double-blind clinical trial wilding jp drug-naive asian patients privacy choices/manage cookies author information authors network meta-analysis national research committee full article pdf edoardo mannucci dose-finding study beneficial action observed comprehensive meta-analysis meta-analysis detected long-term study adequate glycemic control improve glycemic control article monami glucose-regulating drug

Questions {❓}

Gov/ct2/show/NCT01032629?
Gov/ct2/show/NCT01137474?
Gov/ct2/show/NCT01340664?
Gov/ct2/show/NCT01649297?
Gov/ct2/show/NCT01730534?
Gov/ct2/show/NCT01986881?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
         description: EMPAREG OUTCOME study showed a reduction in cardiovascular events in patients treated with the sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin, as compared to placebo. Other drugs of the same class are currently been investigated for cardiovascular outcomes. In the meanwhile, a re-analysis of data collected in available studies can add relevant insight. A MEDLINE search for SGLT-2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, ertugliflozin, luseogliflozin) was performed, collecting all randomized trials up to November 16, 2015. All trials with a duration of treatment ≥12 weeks, enrolling patients with type 2 diabetes, comparing a SGLT2i with placebo or other comparators were included. The principal outcome was the effect of SGLT2i on all-cause and cardiovascular mortality. Secondary endpoints were myocardial infarction and stroke. Mantel–Haenszel odds ratio with 95 % confidence interval (MH-OR) was calculated. A total of 71 trials were included (31,199 and 16,088 patients in SGLT2i and comparator groups). Treatment with SGLT2i was associated with a significant reduction in all-cause mortality (MH-OR 0.70 [0.59–0.83], p < 0.001), cardiovascular mortality (MH-OR 0.43 [0.36–0.53], p < 0.001), and myocardial infarction (MH-OR 0.77 [0.63–0.94], p < 0.01), but not stroke (MH-OR 1.09 [0.86–1.38], p = 0.50), with no apparent difference across molecules (after excluding cardiovascular outcome trials). Available data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. The present meta-analysis showed a significantly reduction in myocardial infarction, with no increased risk of stroke.
         datePublished:2016-08-04T00:00:00Z
         dateModified:2016-08-04T00:00:00Z
         pageStart:19
         pageEnd:36
         sameAs:https://doi.org/10.1007/s00592-016-0892-7
         keywords:
            SGLT-2 inhibitors
            Cardiovascular events
            Mortality
            Meta-analysis
            Internal Medicine
            Diabetes
            Metabolic Diseases
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig6_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig7_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig8_HTML.gif
         isPartOf:
            name:Acta Diabetologica
            issn:
               1432-5233
               0940-5429
            volumeNumber:54
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Milan
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Matteo Monami
               url:http://orcid.org/0000-0001-9349-828X
               affiliation:
                     name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
                     address:
                        name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Ilaria Dicembrini
               affiliation:
                     name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
                     address:
                        name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Edoardo Mannucci
               affiliation:
                     name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
                     address:
                        name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
      description: EMPAREG OUTCOME study showed a reduction in cardiovascular events in patients treated with the sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin, as compared to placebo. Other drugs of the same class are currently been investigated for cardiovascular outcomes. In the meanwhile, a re-analysis of data collected in available studies can add relevant insight. A MEDLINE search for SGLT-2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, ertugliflozin, luseogliflozin) was performed, collecting all randomized trials up to November 16, 2015. All trials with a duration of treatment ≥12 weeks, enrolling patients with type 2 diabetes, comparing a SGLT2i with placebo or other comparators were included. The principal outcome was the effect of SGLT2i on all-cause and cardiovascular mortality. Secondary endpoints were myocardial infarction and stroke. Mantel–Haenszel odds ratio with 95 % confidence interval (MH-OR) was calculated. A total of 71 trials were included (31,199 and 16,088 patients in SGLT2i and comparator groups). Treatment with SGLT2i was associated with a significant reduction in all-cause mortality (MH-OR 0.70 [0.59–0.83], p < 0.001), cardiovascular mortality (MH-OR 0.43 [0.36–0.53], p < 0.001), and myocardial infarction (MH-OR 0.77 [0.63–0.94], p < 0.01), but not stroke (MH-OR 1.09 [0.86–1.38], p = 0.50), with no apparent difference across molecules (after excluding cardiovascular outcome trials). Available data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. The present meta-analysis showed a significantly reduction in myocardial infarction, with no increased risk of stroke.
      datePublished:2016-08-04T00:00:00Z
      dateModified:2016-08-04T00:00:00Z
      pageStart:19
      pageEnd:36
      sameAs:https://doi.org/10.1007/s00592-016-0892-7
      keywords:
         SGLT-2 inhibitors
         Cardiovascular events
         Mortality
         Meta-analysis
         Internal Medicine
         Diabetes
         Metabolic Diseases
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig6_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig7_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00592-016-0892-7/MediaObjects/592_2016_892_Fig8_HTML.gif
      isPartOf:
         name:Acta Diabetologica
         issn:
            1432-5233
            0940-5429
         volumeNumber:54
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Milan
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Matteo Monami
            url:http://orcid.org/0000-0001-9349-828X
            affiliation:
                  name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
                  address:
                     name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Ilaria Dicembrini
            affiliation:
                  name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
                  address:
                     name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Edoardo Mannucci
            affiliation:
                  name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
                  address:
                     name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Acta Diabetologica
      issn:
         1432-5233
         0940-5429
      volumeNumber:54
Organization:
      name:Springer Milan
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
      address:
         name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
         type:PostalAddress
      name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
      address:
         name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
         type:PostalAddress
      name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
      address:
         name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Matteo Monami
      url:http://orcid.org/0000-0001-9349-828X
      affiliation:
            name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
            address:
               name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Ilaria Dicembrini
      affiliation:
            name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
            address:
               name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
               type:PostalAddress
            type:Organization
      name:Edoardo Mannucci
      affiliation:
            name:Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence
            address:
               name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
      name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
      name:Diabetology, Azienda Ospedaliero-Universitaria Careggi, Careggi Teaching Hospital, University of Florence, Florence, Italy
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(285)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.22s.

LINK . SPRINGER . COM {}